2Dornadula G,Zhang H, VanUitert B, et al . Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretrovlral therapy[J]. JAMA, 1999,282 : 1627-1632.
3Andrew N. Phillips, Alessandro Cozzi Lepri. Fiona Lampe, et al. When should antire-troviral therapy be started for HIV infection Interpreting the evidence from obse - rvational studies [ J ].AIDS,2003,13,1863-1869.
4Hammer SM, Saag MS, SeheehterM, et al . Treatment for adult HIV infection; 2006 recomm-endations of the International AIDS Society-USA panel[J]. JAMA, 2006,296:827-843.
6Andrea Cossanzza, Graeme Moyle. Antiretroviral nudeoaide and nucleotide analogues and mitochon-dria [J]. AIDS, 2004, 2: 137- 151.
7LeonA, Mallolas J, MartinezE, et al . High rate of virological failure in maintenance antiretrovlral therapy with didanosine and tenofovir[J]. AIDS, 2005,19 : 1 695-1 697.
8Reinke, R, Steffen NR. Robinson WE Jr. Natural selection results in conservation of HIV-1 integrase activity despite sequence variability[J]. AIDS, 2001,15 : 823.
9Walensky RP. Paltiel AD, Losina E, et al . I, he survival benefits of AIDS treatment In the United States[J]. The Journal of Infectious Diseases, 2006,194 : 11-19.
10Vella S V. Palmisano L. Antiretroviral therapy; state of the HAART[J], Antiviral Res, 2000,45 : 1-7.
